U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease

{
  "signal_id": "44a1ff12-6034-c200-e416-3532b6042574",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-09-28T12:00:00+00:00",
  "company": {
    "name": "AbbVie",
    "domain": "abbvie.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/us-fda-approves-abbvies-juvmo-tavapadon-for-parkinsons-disease-302890715.html",
    "title": "U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease",
    "excerpt": "NORTH CHICAGO, Ill. , Sept. 28, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV ) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease, a progressive neurological disorder that affects millions of people worldwide. JUVMO Is a New Kind of Treatment for Parkinson's Disease \"The approval of JUVMO marks the first dopaminergic breakthrough for Parkinson's disease in decades,\" said Roopal Thakkar, M.D., executive vice president, research and development, chief scientific officer, AbbVie. \"People living with Parkinson's and the clinicians who care for them have long faced difficult tradeoffs between motor control, treatment burden and tolerability. Clinicians now have a new treatment option that targets dopamine pathways differently and reduces the difficult tradeoffs associated with D2/D3 selective dopamine agonists.\" Needed Innovation in the Parkinson's Disease Treatment Landscape For people living with Parkinson's disease, maintaining consistent control of motor symptoms becomes increasingly challenging as the disease progresses. Oral levodopa remains the foundation of treatment and is often effective at controlling symptoms, but many patients require higher and more frequent doses over time. These adjustments can help restore...",
    "product": "JUVMO",
    "summary": "AbbVie's Parkinson's disease treatment, JUVMO™ (tavapadon), has been approved by the U.S. Food and Drug Administration (FDA) and is expected to be available to patients in the U.S. in October 2026.",
    "location": "United States",
    "planning": false,
    "confidence": 1,
    "product_data": {
      "name": "JUVMO",
      "full_text": "JUVMO™ (tavapadon) tablets",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical",
      "general_technology"
    ],
    "published_at": "2026-09-28T12:00:00Z",
    "location_data": [
      {
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-10-01",
    "article_sentence": "Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease, a progressive neurological disorder that affects millions of people worldwide."
  }
}

curl https://signals.autobound.ai/v1/signals/44a1ff12-6034-c200-e416-3532b6042574 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"abbvie.com","limit":20}'